Acute Coronary Syndrome — NSTEMI/Unstable Angina

Key Points

• Use serial high-sensitivity troponin and serial ECGs; one normal result early after symptom onset may be insufficient.
• An elevated troponin is myocardial injury, not automatically type 1 myocardial infarction.
• Aspirin is foundational unless contraindicated, and acute anticoagulation is used in confirmed or strongly suspected NSTE-ACS according to strategy.
• Do not give fibrinolytic therapy for NSTEMI or unstable angina.
• Very-high-risk patients with shock, refractory ischemia, or malignant arrhythmia require urgent invasive evaluation.
• Assess bleeding risk alongside ischemic risk before choosing antithrombotic intensity and duration.
• High-intensity statin therapy and long-term risk-factor treatment should begin during the index admission.
• New ischemic ECG changes or recurrent pain require reassessment even after an initially reassuring workup.

Algorithm

1. Obtain immediate ECG, vital signs, focused examination, and high-sensitivity troponin.
2. Treat ongoing ischemia and give aspirin unless contraindicated while excluding aortic dissection and other diagnoses that make antithrombotic therapy hazardous.
3. Repeat ECG and troponin using the institution's validated accelerated diagnostic pathway.
4. Classify the syndrome as STEMI, NSTEMI, unstable angina, nonischemic myocardial injury, or another diagnosis.
5. For NSTE-ACS, start appropriate anticoagulation and plan P2Y12 therapy around the invasive strategy and bleeding risk.
6. Escalate immediately for shock, refractory symptoms, dynamic high-risk ECG changes, or life-threatening arrhythmia.
7. Perform risk-guided coronary angiography and revascularization when indicated.
8. At discharge, optimize antiplatelet therapy, statin treatment, smoking cessation, cardiac rehabilitation, blood pressure, diabetes, and follow-up.

Clinical Synopsis & Reasoning

Symptoms may include pressure, heaviness, tightness, burning, dyspnea, diaphoresis, nausea, or unexplained weakness rather than classic central chest pain. Older adults, people with diabetes, and women may present with less typical symptom patterns, but these features do not make ischemia benign. Obtain a 12-lead ECG within minutes of arrival and repeat it when symptoms recur or the first tracing is nondiagnostic. Dynamic ST depression, transient ST elevation, or T-wave changes increase ischemic concern. High-sensitivity cardiac troponin should be measured using a validated rapid serial algorithm; a rise or fall above the assay-specific 99th percentile supports acute myocardial injury, but infarction additionally requires clinical evidence of ischemia. Troponin elevation can also occur with pulmonary embolism, myocarditis, sepsis, tachyarrhythmia, heart failure, kidney disease, and other conditions. Bedside examination should identify shock, heart failure, a new murmur suggesting mechanical complication, unequal pulses suggesting aortic disease, or findings of another diagnosis. Risk assessment includes hemodynamic status, recurrent pain, ECG changes, troponin, ventricular function, kidney function, bleeding risk, and validated tools such as GRACE when useful. Immediate invasive evaluation is appropriate for refractory ischemia, shock, life-threatening arrhythmia, or other very-high-risk features.

Treatment Strategy & Disposition

Give chewable aspirin promptly unless there is a true contraindication. Add a P2Y12 inhibitor according to the planned strategy, anatomy, bleeding risk, and whether PCI is performed. The 2025 ACC/AHA acute coronary syndrome guideline recommends ticagrelor or prasugrel over clopidogrel in many patients undergoing PCI, while pretreatment before coronary anatomy is known should be individualized. Use parenteral anticoagulation during the acute phase with unfractionated heparin, enoxaparin, or another guideline-supported agent selected for strategy and renal function. Nitrates can relieve ischemic discomfort and hypertension but should be avoided in hypotension, suspected right ventricular infarction, or recent phosphodiesterase-5 inhibitor exposure. Beta blockade is useful in appropriate stable patients but is avoided in shock, severe acute heart failure, marked bradycardia, or high-grade block. Start high-intensity statin therapy early. An invasive strategy is recommended during hospitalization for most intermediate- and high-risk NSTEMI patients, with urgent angiography for instability. Fibrinolysis is not a treatment for NSTEMI or unstable angina. After PCI, default dual antiplatelet therapy is generally 12 months when bleeding risk is not high, with shorter or modified strategies for selected patients.

Epidemiology / Risk Factors

• Acute coronary syndromes remain a major cause of morbidity and mortality worldwide.
• Use of high-sensitivity troponin has shifted many cases formerly labeled unstable angina into NSTEMI or nonischemic myocardial injury categories.
• Major risk factors include age, smoking, hypertension, dyslipidemia, diabetes, chronic kidney disease, and established atherosclerotic disease.
• Women and older adults may be under-recognized when clinicians rely on stereotyped chest-pain descriptions.
• Prior coronary disease raises pretest probability but does not remove the need to evaluate competing emergencies.

Investigations

Antithrombotic Options (Initial)

Pharmacology

Prognosis / Complications

• Risk is highest with shock, recurrent ischemia, large troponin elevation, dynamic ECG abnormalities, reduced left ventricular function, kidney disease, and extensive coronary disease.
• Timely invasive management and contemporary antithrombotic therapy reduce recurrent ischemic events in appropriately selected high-risk patients.
• Bleeding events are independently associated with worse outcomes, so prevention is an integral part of ACS management.
• Cardiac rehabilitation and aggressive secondary prevention improve long-term cardiovascular outcomes.
• Recurrent symptoms after discharge require urgent reassessment because stent thrombosis, recurrent infarction, arrhythmia, or heart failure can occur.

Patient Education / Counseling

• Explain the difference between myocardial infarction, unstable angina, and other causes of troponin elevation.
• Emphasize exact adherence to dual antiplatelet therapy after stenting and instruct patients not to stop it without contacting the treating cardiology team.
• Review bleeding warning signs and interactions with NSAIDs or anticoagulants.
• Encourage cardiac rehabilitation, smoking cessation, lipid lowering, physical activity, and control of blood pressure and diabetes.
• Advise emergency evaluation for recurrent pressure-like chest discomfort, dyspnea, syncope, or new diaphoresis rather than self-monitoring at home.

Notes

NSTE-ACS care depends on distinguishing plaque-mediated ischemia from the many other causes of chest symptoms and troponin release. Rapid ECG and high-sensitivity troponin pathways improve diagnostic speed, but the result still has to be interpreted clinically. Once NSTE-ACS is established, the central decisions are how urgently the patient needs angiography, which antithrombotic regimen provides the best ischemic protection with acceptable bleeding risk, and how to build durable secondary prevention before discharge. Instability overrides routine timing: shock, recurrent ischemia, or malignant arrhythmia requires immediate escalation.

References

1. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes — Link